Abstract
Inhibiting the molecular evolution of cancer through HSP90.
Highlights
Myelodysplastic syndromes (MDS) are a very heterogeneous group of conditions affecting the hematopoietic system
Phase I and II clinical studies have shown promising results for heat shock protein 90 (HSP90) inhibitors in malignancies addicted to particular HSP90 clients, especially HER2+ trastuzumabrefractory breast and EGFR-mutant and ALK-translocated non small cell lung cancer, as well as other opportunities in haematological cancers, including multiple myeloma and leukaemias driven by HSP90 clients (4)
Previous studies in a large series of acute myeloid leukaemia (AML) patients revealed an association between higher expression levels of HSP90 and poor prognosis together with enhanced activation of oncogenic signaling pathways involving PI3 kinase, AKT and ERK1/2 (6)
Summary
Myelodysplastic syndromes (MDS) are a very heterogeneous group of conditions affecting the hematopoietic system. The importance of HSP90 in cancer is well established, in particular its role in supporting the active conformation of many oncogenic client proteins (4).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
